Dr Rajesh Jain, joint managing director at Panacea Biotec, tells NDTV that the company has received a $25 million upfront payment for the supply of two delivery-based generic products. After commercialisation of the drugs, there will be a profit sharing ratio of 50:50 between Panacea Biotech and Canada's Apotex.
